Aurinia Pharmaceuticals Inc AUPH:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:58 PM EST
14.00UNCH (UNCH)
Volume
19,474
Close
14.00quote price arrow down-0.58 (-3.98%)
Volume
4,755,714
52 week range
9.83 - 20.50

...

Loading . . .

KEY STATS

  • Open14.58
  • Day High14.87
  • Day Low13.85
  • Prev Close14.58
  • 52 Week High20.50
  • 52 Week High Date01/25/21
  • 52 Week Low9.83
  • 52 Week Low Date03/18/20
  • Market Cap2,037.75M
  • Shares Out126.45M
  • 10 Day Average Volume3.49M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-23.71

RATIOS/PROFITABILITY

  • EPS (TTM)-1.47
  • P/E (TTM)-9.53
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/12/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Aurinia Pharmaceuticals Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. It is developing voclosporin in multiple indications. Voclosporin is an investigational therapy. It is developing voclosporin for the treatment of lupus nephritis (LN) and other proteinuric diseases. It is also advancing voclosporin ophthalmic solution...
George Milne Jr., Ph.D.
Chairman
Peter Greenleaf
President
Michael Martin
Chief Operating Officer
Dennis Bourgeault CPA
Chief Financial Officer
Robert Huizinga
Executive Vice President
Fran Lynch
Vice President
Address
1203-4464 Markham St
Victoria, BC
V8Z 7X8
Canada